Autologous bone marrow‐derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single‐center, open‐label TRITON study

After renal transplantation, there is a need for immunosuppressive regimens which effectively prevent allograft rejection, while preserving renal function and minimizing side effects. From this perspective, mesenchymal stromal cell (MSC) therapy is of interest. In this randomized prospective, single...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinders, Marlies E. J., Groeneweg, Koen E., Hendriks, Sanne H., Bank, Jonna R., Dreyer, Geertje J., de Vries, Aiko P. J., van Pel, Melissa, Roelofs, Helene, Huurman, Volkert A. L., Meij, Paula, Moes, Dirk J. A. R., Fibbe, Willem E., Claas, Frans H. J., Roelen, Dave L., van Kooten, Cees, Kers, Jesper, Heidt, Sebastiaan, Rabelink, Ton J., de Fijter, Johan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518640/
https://www.ncbi.nlm.nih.gov/pubmed/33565206
http://dx.doi.org/10.1111/ajt.16528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518640/
https://www.ncbi.nlm.nih.gov/pubmed/33565206
http://dx.doi.org/10.1111/ajt.16528

Ejemplares similares